MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2023

Aug 30, 2023

==> picture [210 x 53] intentionally omitted <==

==> picture [491 x 27] intentionally omitted <==

FY23 Investor Presentation August 31, 2023

Mach7 Technologies ASX: M7T

1

Disclaimer “forward looking” statements

==> picture [960 x 23] intentionally omitted <==

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forwardlooking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

2

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Agenda
----- End of picture text -----

• Business Overview FY23 Results Outlook •

• • Full-Year Highlights About Mach7

• • Our Purpose • Record Sales Orders –

• • Subscription weighting Appendices Our Solution – New customer & partners

• • Our Scalable Framework • Major Contract Wins

• • Our AI Position • Revenue Composition

• • Our Markets • Recurring Revenue

• • Our Customer Composition • Strong Financials

• • Our Product Rankings • Corporate Update

3

Unless otherwise stated, all dollar values are in Australian dollars (AUD) .

==> picture [960 x 63] intentionally omitted <==

Business Overview

==> picture [491 x 343] intentionally omitted <==

4

Issued 18 February 2021, approved by the Board

4

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

About Mach7
----- End of picture text -----

Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem.

We give healthcare organisations the independence and flexibility to deploy our solutions according to their needs, either through individual product components or via a unified, comprehensive end-to-end enterprise imaging platform. In this way we help our customers to improve efficiency, achieve operational cost savings, leverage their existing IT investments, improve the experience for patients and medical professionals, and support healthier outcomes.

(ASX:M7T)

==> picture [487 x 408] intentionally omitted <==

5

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Purpose
----- End of picture text -----

Vision:

We believe every healthcare organization should be an open and connected environment where patient information flows easily and can be viewed and accessed instantly.

Mission:

Our mission is to become the definitive technology partner that guides healthcare organisations through their transformation from unconnected, standalone imaging departments to an open, vendor neutral, integrated healthcare enterprise.

==> picture [487 x 408] intentionally omitted <==

6

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Solution – Enterprise Imaging Platform
----- End of picture text -----

Enterprise Data Management

Enterprise Diagnostic Viewing

Departmental Workflow Applications

Vendor Neutral Archive

eUnity Enterprise Diagnostic Viewer

Reading & Departmental Workflow

• Allows customers to take control of their data

• Leverage existing I.T. infrastructure

• Consolidate ALL Images across enterprise

• Store in native format or wrap in DICOM

• Enhanced data security

• Develop customer workflow routing

• Data normalization through tag morphing

• Integration framework for 3[rd] party clinical systems

• Built in data anonymization tools

• On premise or via cloud infrastructure

• Top-tier, KLAS-rated ZFP Enterprise Viewer

• 100% fidelity images

• Image enable the EMR

• Browser agnostic-HTML-5

• Independence from front end clinical systems

• Image enablement for downtime PACS solution

• Leverage existing IT Infrastructure

• Reduces cost and complexity across enterprise

• Facilitate image sharing and clinical collaboration

• Research and AI test platform

• Universal Worklist

• Supports 3[rd] party VR integration

• DMWL

• Zero footprint, browser agnostic viewer

• Breast imaging reading and workflow

• 3D, MIP, MPR

• User communication module

• QC module

• Open platform supporting 3[rd] party solutions

• Reduces cost and complexity

7

Our Scalable Framework

==> picture [960 x 23] intentionally omitted <==

==> picture [8 x 325] intentionally omitted <==

==> picture [105 x 105] intentionally omitted <==

Build on Existing Work

Builds upon the substantial work done in the medical imaging sector to accept standard based information exchange. This allows stakeholders to utilise and exchange data across organisational boundaries.

==> picture [8 x 325] intentionally omitted <==

==> picture [105 x 104] intentionally omitted <==

Allow Anyone to Join

Provides a point of access to allow all types of healthcare stakeholders to participate with a complete medical record which includes image availability. Regardless of the vendor used.

==> picture [8 x 325] intentionally omitted <==

==> picture [104 x 104] intentionally omitted <==

Innovative Technologies

Allows new and innovative technologies such as AI to enter the enterprise to overlay and build solutions that make use of the data.

==> picture [8 x 325] intentionally omitted <==

==> picture [104 x 104] intentionally omitted <==

Long-Term Scalability

Ensures variation around a broader set of use cases and provides long-term scalability for participants and end-users.

8

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our AI Position
----- End of picture text -----

AI Market Dynamics:

• According to Signify Research, the medical imaging AI market was estimated at US$576 million and is forecast to reach almost US$1.75 billion by 2027

• Major drivers for the use of AI in medical imaging include the increasing number of imaging procedure volumes creating additional workload for radiologists as well as the introduction of new reimbursements for AI adoption in the US.

• M&A activity has commenced with 9 acquisitions in the last year, including pharmaceutical giant, Bayer, acquiring Blackford Analysis, and ultrasound modality vendors GE Healthcare and Philips acquiring Caption Health and DIA Imaging Analysis respectively.

AI Ready - Data Storage, Management & Orchestration

Deployment, integration, data depth, data management and data orchestration are key requirements for AI enablement

==> picture [428 x 134] intentionally omitted <==

Mach7 VNA

Mach7 Data Pool

• Barriers remain for widespread adoption of AI with reimbursement limited across all clinical segments, especially beyond the US; a lack of evidence demonstrating the health economic benefits, including return-on-investment for providers; and the regulatory process to enable commercialisation of algorithms is lengthy and expensive for AI vendors.

Total contracted annual studies archived (new studies only): >30,000,000 Annual study range (smallest to largest customer): 10,000 to 6,500,000

Migrated studies are also stored in VNA (examples of large migrations): 22.6M,16M studies, 300 TB etc.

9

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Markets
----- End of picture text -----

Diverse Market Segments and Global Footprint

• Integrated Delivery Networks (IDNs)

165+ Customers in 15 Countries

• US public health system (new market in FY24)

==> picture [551 x 298] intentionally omitted <==

• International hospital authorities

• Regional and community hospital systems

• Academic medical institutions

• Medical research facilities

• Independent provider groups

• Imaging Centres

• Teleradiology service providers

• Strategic partnerships

• Children’s health centres

10

Our Customer Composition

==> picture [960 x 23] intentionally omitted <==

Customer & Product Profile[1]

ClientOutlook Acquisition Impact

• Acquisition Date: 14 July 2020

• Acquisition cost: $35M

• Revenue at Acquisition: $8M

• Single product – eUnity Diagnostic Viewer

• Previously a tender partner with Mach7 VNA

• Previously Mach7 was a reseller of eUnity Viewer

• Complete product suite – front & back-end post FY20

• FY23 sales order value predominantly VNA + Viewer or cross-selling of Viewer to existing VNA customers

• Sales pipeline has grown 4-fold since acquisition

==> picture [440 x 214] intentionally omitted <==

----- Start of picture text -----

$25.0
$20.0
$15.0
$10.0
$5.0
$-
Cross Sales Viewer Only VNA + Viewer VNA Only
FY 2020 FY 2021 FY 2022 FY 2023
Sales Orders TCV (A$M)
----- End of picture text -----

==> picture [225 x 160] intentionally omitted <==

FY23 Sales Orders by Number of Customers

==> picture [153 x 34] intentionally omitted <==

==> picture [291 x 30] intentionally omitted <==

----- Start of picture text -----

Viewer VNA Cross Sales
17 7 7 6
----- End of picture text -----

11

1. Excludes Professional Services component of sales orders. “Cross Sales” means the customer had one product then bought the other; “VNA + Viewer“ means the customer bought both products together.

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Product Rankings
----- End of picture text -----

Best in KLAS 2023: Universal Viewer Segment

==> picture [51 x 51] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

Placed #2 overall for second year in a row

==> picture [51 x 51] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Held the #1 spot for most of CY 2022

==> picture [51 x 51] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

Currently in #1 rank in live data in KLAS*

==> picture [51 x 51] intentionally omitted <==

----- Start of picture text -----

96%
----- End of picture text -----

Notable performance: 96% “yes” response to “Would you buy again.”

==> picture [248 x 318] intentionally omitted <==

Mach7 VNA (Vendor Neutral Archive)

==> picture [52 x 51] intentionally omitted <==

Ranked alongside large legacy PACS vendors by KLAS including GE, Agfa and Philips.

V12 of the Mach7 VNA being rolled out at customer sites; expected to drive scores up over the coming year.

==> picture [51 x 51] intentionally omitted <==

----- Start of picture text -----

v12
----- End of picture text -----

CIO, on functionality and upgrades: “Mach7

Technologies is really configurable. It allows us to do things that other VNAs haven’t been able to do. We interact with other vendors’ VNAs at other locations, and those VNAs don’t have any of the same flexibility that we have in Mach7 Technologies’ system. We couldn’t do what we do without Mach7 Technologies’ system.” Provided to KLAS Research January 2023

12

• on 4 Aug 2023

==> picture [960 x 63] intentionally omitted <==

FY23 Results

==> picture [491 x 343] intentionally omitted <==

Issued 18 February 2021, approved by the Board 13 13

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Full Year Highlights
----- End of picture text -----

==> picture [656 x 400] intentionally omitted <==

----- Start of picture text -----

Record Sales Orders CARR [3]
(TCV) [1 ] Record Revenue $20.6M
$40.3M $30.1M +$3.6M or 21% on PCP
+$3.0M or 11% on PCP
+$7.1M or 21% on PCP [2] $24.8M at July 2023
New contracts in EBITDA (adjusted) [5] NPAT
high growth market $2.5M -$1.0M
Akumin -$1.3M or -34% on PCP +$3.1M or 75% on PCP
Nuvodia NPATA [6]
VHA & DIA in Q1 FY24 $7.2M
+$2.8M or 61% on PCP
----- End of picture text -----

==> picture [204 x 185] intentionally omitted <==

----- Start of picture text -----

ARR [4]
$17.0M run rate
+$2.6M or 18% on PCP
$17.7M run rate July 2023
----- End of picture text -----

==> picture [203 x 186] intentionally omitted <==

----- Start of picture text -----

Strong financial position
Cash: $23.4M 30 June 23
$25.9M 3 July 23
no debt
----- End of picture text -----

1. TCV – Total Contract Value; 2. PCP – Prior Corresponding Period.; 3. CARR: Contacted Annual Recurring Revenue; 4. ARR: Annual Recurring Revenue; 5. EBITDA adjusted for 14 foreign exchange impacts and non-cash share-based payments; 6. NPATA: (Net Profit After Tax and before Amortisation) is NPAT adjusted for amortisation of acquired intangibles

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Record Sales Orders – Subscription Weighting
----- End of picture text -----

Recurring revenue continues to be a feature of sales orders

Sales Orders by Fee Type (TCV)

Highlights:

• Record sales orders of $40.3M (TCV), up 21% on FY22 (+12% in constant currency[1] ) and exceeding FY23 target of $36M. Sales orders are the best measure of financial progress as cash receipts and revenue recognition are affected by contract milestones and licence fee type

• ARR (Subscription/Support & Maintenance) sales orders account for 58% of total sales in FY23 (v 58% in FY22 and 49% in FY21). Approximate 60/40 subscription/capital deals maintained

• Brand recognition improving with increasing usage – consultant network effect and continued top KLAS rankings – evidenced by significant contract wins in FY24

• On track to hit 20% sales order growth target of $48M following a strong start to FY24 with over $15.4M TCV of sales orders secured in the first month and $31M of contract renewals[2] expected within the fiscal year

==> picture [420 x 297] intentionally omitted <==

----- Start of picture text -----

45
40
35 49% 58%
32%
30
32%
25
10%
20 35% 10%
15 16%
58%
10
58%
49%
5
0
FY21 FY22 FY23
Subscription/Support & Maintenance Professional Services Capital Software
Sales Orders (A$M)
----- End of picture text -----

15

1. At average exchange rate for FY23 of AUD/USD $0.673

2. Including ~$11M Support & Maintenance contract renewal for HAHK perpetual licence

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Record Sales Orders – New Customers and Partners
----- End of picture text -----

New customers strengthen base for further growth

FY23 Sales Orders by Order Type (TCV)

Highlights:

• New customer sales orders of $22.1M (55% of total sales orders) represented 3 new logos: Akumin, Nuvodia and St Paul’s Hospital Hong Kong. New customers create a platform for future sales order growth in expansion, add-on and renewal categories.

• Add-ons of extra products or services represented $3.2M (8% of total sales orders) and is evidence of the “land and expand” sales strategy.

• Expansion/Fulfilment represented $9.6M (24% of total sales orders). Existing customer, Adventist Health, accounted for approximately 75% of this category having signed sales orders during the period for its remaining 15 (of 22) hospitals that were yet to deploy Mach7’s PACS.

• Renewals of $5.3M (13% of total sales orders) represented 19 satisfied customers. Expect a more significant contribution in FY24 with ~$31M of contract renewals[2] .

• Partnerships have increasingly contributed to sales order growth, accounted for 13% of total sales orders in FY23 (up on 8% in FY22)

==> picture [413 x 130] intentionally omitted <==

----- Start of picture text -----

Add-on
$3.2 M
Expansion
8%
$9.6 M New
24% $22.1 M
55%
Renewal
$5.3 M
13%
----- End of picture text -----

Renewal Profile[1] (TCV)

==> picture [398 x 178] intentionally omitted <==

----- Start of picture text -----

18
16
14
12
10
8
6
4
2
0
FY24 FY25 FY26 FY27 FY28 FY29 FY30 FY33
Capital Subscription Annual Support 2
Scheduled Reneals (A$M)
----- End of picture text -----

1. Renewal dates are tied to FPU rather than effective contract date; where FPU is yet to be achieved, the date has been estimated. Each renewal is only included once in the period shown. TCV represents original contract price net of Professional Service fees. Data excludes customers on annual auto-renewal Support & Maintenance contracts including Advocate Aurora and Trinity

16

2. Including ~$11M Support & Maintenance contract renewal for HAHK perpetual licence

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Major Contract Wins
----- End of picture text -----

New customers expand geographic and sectoral footprint

FY23 Highlights – New Customers Buy Entire Enterprise Imaging Platform:

• St. Paul’s Hospital HK - a private hospital with ~500 beds and more than 20 departments. The capital contract has TCV of $1.52M.

• Nuvodia - a US radiology and IT service provider focusing on outpatient imaging centres. The subscription contract has a 5-year term with a TCV of $2.5M.

• Akumin – an outpatient radiology service provider with a network of 234 outpatient radiology and oncology centers and approximately 1,000 hospitals and health system clients across 48 states. The capital contract has a 10-year term with TCV of $16.7M.

Q1 FY24 Highlights – Public Sector Entry and Outpatient Focus:

• Veterans Health Administration (VHA) - National Teleradiology Program (NTP) contract. Phase I will see Mach7’s VNA and eUnity viewer solutions form the core of NTP’s NextGen PACS and has a potential TCV of $11.7 million with a 12-month implementation fee period then a fee/study subscription licence over a 3-year term.

• Diagnostic Imaging Associates (DIA) – an onsite and teleradiology service provider to public and private radiology departments throughout Oklahoma and surrounding states. The subscription contract has a TCV of $3.7M and a 5-year term.

==> picture [347 x 374] intentionally omitted <==

17

Revenue Composition Predominantly Recurring

==> picture [960 x 23] intentionally omitted <==

Highlights:

• Record revenue of $30.1M, up 11% on $27.1M in FY22

• Revenue growth of $3.0M was impacted by the reclassification of $1.7M Akumin revenue to interest income over the 10-year contract term and the $3.7M DIA contract which was expected to be capital rather than subscription and fall in FY23 rather than Q1 FY24.

• Revenue growth trails sales order growth as recognition of subscription/support and maintenance components of new orders require FPU which can take 6-18 months

• Product revenue split approximately 60/40 between VNA and Viewer in FY23 with Viewer revenue up 15% on FY22.

• Recurring revenue continues to grow as a proportion of total revenue and now represents 54% of total revenue vs 49% in FY22.

==> picture [448 x 400] intentionally omitted <==

----- Start of picture text -----

FY 2023 FY 2022 % Change
Enterprise Diagnostic
12.3 M 10.7 M 15%
Viewing (eUnity)
Enterprise Data
17.8 M 16.4 M 9%
Management (VNA) [1]
Total 30.1 M 27.1 M 11%
Revenue Composition
35
30
25
37%
20 40%
9%
15 11%
10
49% 54%
5
0
FY18 FY19 FY20 FY21 FY22 FY23
Recurring Revenue Professional Service Revenue Capital Licence Revenue
CAGR 37%
Revenue (A$M)
----- End of picture text -----

1. Includes Departmental Workflow Applications

18

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Recurring Revenue Trending Higher
----- End of picture text -----

Recurring revenue growth

Highlights:

• Contracted Annual Recurring Revenue (CARR) of $20.6M, up 21% on $17.0M at June 2022. Post balance date, two significant contracts (VHA and DIA) improved CARR to $24.8M at July 2023. CARR is the lead indicator for ARR

• Annual Recurring Revenue (ARR) Run Rate of $17.0M, up 18% on $14.4M at June 2022. With Trinity Health achieving FPU in June 2023, the ARR run rate at July 2023 was $17.7M

• Differential - the $7.1M difference between CARR and the ARR run rate at July 2023 represents the time lag for software going live and includes Akumin, Adventist, VHA and DIA contracts

• Low customer churn representing <1% of revenue and <2% of customer numbers

• Continue to track at ~65% coverage of operating expenses by ARR run rate. Target 100% within 3 years

==> picture [488 x 375] intentionally omitted <==

----- Start of picture text -----

Recurring Revenue: CARR v ARR
28
24 $7.1M
yet to reach
FPU
20
16
12
8
4
0
FY18 FY19 FY20 FY21 FY22 FY23 Jul-23
ARR (Run Rate) CARR
Recurring Revenue (A$M)
----- End of picture text -----

19

ARR Run Rate: the year-to-date monthly average of revenue earned from support & maintenance fees and subscription fees, annualised CARR: ARR Run Rate + annual subscription and support fees where FPU is yet to occur; FPU: First Productive Use

Strong Financials

==> picture [960 x 23] intentionally omitted <==

NPAT uplift, healthy cash balance, no debt

Highlights:

• Revenue growth of 11% ($3.0M) was impacted by reclassification of Akumin revenue to interest income as well as the timing and type of DIA contract. Expect revenue growth of 15-25% in FY24.

• Cost growth moderated from 28% in FY22 to 19% in FY23. Expect similar opex growth in FY24 given cost inflation, salary actions plus support and development team hires.

• EBITDA (adjusted) of $2.5M was impacted in part by the exclusion of Akumin interest income.

• NPAT up 75% and NPATA up 61% , driven by increased income tax benefits reflecting projections that Mach7 will soon utilise prior year tax losses against profitable positions. R&D is expensed rather than capitalised - amortisation relates only to acquisition costs.

• Operating Cash flow impacted by delayed $2.5M payment receipt, one-off staff costs, increased professional fees and travel expenses.

• $25.9M cash at commencement of FY24 and no debt.

Earnings	FY23	FY22	% Change
Revenues	30.1M	27.1 M	+11%
Distributor Fees	(1.0M)	(1.0M)	-
Gross Margins %	97%	96%	-
Operating Expenses	26.5	22.3M	+19%
EBITDA	1.7M	2.8M	-39%
EBITDA (adjusted)1	2.5M	3.8M	-34%
NPAT	-1.0M	-4.2M	+75%
NPATA2	7.2M	4.4M	+61%
Cashflow	FY23	FY22	% Change
Cash Receipts	24.6M	28.2M	-13%
Net Operating CF	-2.6M	6.4M	-141%
Closing Cash Balance	23.4M	25.7M	-9%
Cash Balance 3 July 23	25.9M

20

1. EBITDA adjusted for foreign exchange impacts and non-cash share-based payments 2. NPATA: (Net Profit After Tax and before Amortisation) is NPAT adjusted for amortisation of acquired intangibles

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Corporate Update
----- End of picture text -----

Board Renewal Process Commenced:

David Chambers will retire as Chair and Non-Executive Director of Mach7, effective from the close of the Company’s Annual General Meeting on 16 November 2023. David joined the Mach7 Board in August 2018 as an independent Non-Executive Director and was appointed to the role of Chair in June 2019. David’s retirement marks the five-year anniversary of his tenure. The Board thanks David for his significant contribution and service to the Company.

==> picture [85 x 88] intentionally omitted <==

Corporate Restructure:

Dyan O’Herne was confirmed as Chief Financial Officer having acted in the role from the beginning of the calendar year. Dyan has been an integral member of the leadership team for many years as global financial controller, and with her deep knowledge of Mach7’s customers and cashflows has transitioned seamlessly into the CFO role.

==> picture [85 x 88] intentionally omitted <==

David Madaffri was appointed to the role of Chief Operating Officer. Dave has led Mach7’s commercial efforts for the last two years as Vice President of Sales. During that time, the Company has seen record sales growth and the evolution of a strong corporate culture. With Dave in this role, cohesion will be further enhanced across the Service, Support, Sales, Marketing and People & Culture teams.

==> picture [83 x 88] intentionally omitted <==

Patent Litigation Appeal Update:

A court date has been set for AI Visualize Inc’s appeal of the dismissal of its patent infringement case against Nuance Communications Inc. with the United States Court of Appeals for the Federal Circuit to hear oral arguments on 5 October 2023. The appellate courts do not retry cases nor hear new evidence, and there is no jury. Appellate courts review the procedures and the decisions in the trial court to make sure that the proceedings were fair and that the proper law was applied correctly. The United States District Court for the District of Delaware dismissed AI Visualize’s claims of wilful infringement on the grounds that the patents were not eligible for patenting.

==> picture [89 x 57] intentionally omitted <==

21

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Outlook
----- End of picture text -----

Fragmentation opportunities

Complex opportunities

Renewal opportunities

Sales pipeline opportunities

Fragmented imaging market with long-time legacy vendors losing market share. Dynamics continuing to skew toward ambulatory from acute care settings. Opportunities created for Mach7’s enterprise imaging products which serve both markets.

More complex reading environments and remote workforces becoming the norm. Enterprise imaging strategies require innovation and interoperability to give hospital networks and private groups a simplified image management and diagnostic viewing solution from any location.

Large FY24 renewal program will provide the opportunity to re-price and extend license terms. Generating additional revenue in some cases and

extending contract life cycles in other cases. .

Largest and most diverse pipeline of sales opportunities in Mach7 history. FY24 expectations: • 20% sales order growth

• 15-25% revenue growth

• • Lower opex growth than revenue growth

• • Cashflow positive in FY24

22

==> picture [187 x 47] intentionally omitted <==

Thank You

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Value Proposition
----- End of picture text -----

Fits Individual Needs

We can fit into customers’ existing technology infrastructure or adapt as it changes, such as in the number of servers at a customer site or whether they are centralised, in the cloud, or a hybrid.

Designed for the Enterprise

The foundation is in the enterprise, not individual departmental systems. The Mach7 platform and its modular software solutions have focused on integration, workflow, scalability, and performance.

Flexible Workflows

Flexibility of workflows – with an intuitive and graphical interface, users can customise workflows to meet the needs of individual departments and users.

Lasting Technology

Our software-only solution can stay with customers even as their hardware changes over time. It easily scales to adapt to the customer’s changing environment, such as additional sites acquired due to mergers.

Solves Immediate Needs

The modularity of the solution allows users to implement only the features they absolutely need, and its software-only design is capable of being used on customers’ existing IT infrastructure.

Customer Partnerships

We value our customers’ input and have taken measures to ensure open lines of communication to ensure their feedback reaches us.

Flexible Contract Terms

Cutting Edge Technology

Global Company

Mach7’s modular solution allows us to offer flexible contractual agreements that fit the varying budgetary needs of healthcare organisations.

Our solutions give organisations a connected, vendor neutral infrastructure built on a modern technology stack that allows them to grow, adapt and innovate.

Mach7 is a global company with a focus on healthcare imaging. Because of our size relative to the biggest industry players, we have the agility and flexibility to adapt quickly.

24

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

Our Differentiators
----- End of picture text -----

• Enterprise First Strategy

  • ‘Top Performer’ Product Rankings

• VNA backend data management solution designed and built for entire healthcare network rather than the radiology department

• Interoperable Platform

• Works with existing and future hospital technology - allows image enablement of the EMR and integration of advanced clinical applications and tools, including AI

  • Mach7’s Viewer ranked #2 by independent customer survey (KLAS Research). Features include intuitive usability, advanced clinical workflow tools and diagnostic viewing

• Zero Footprint Viewer

  • Instant access to patient medical images on any device via EMR or web browser without requirement for additional software or plugins

• Tech Stack Independence

• Cloud Compatibility

• Promotes customer control of tech stack via Mach7 module or end-to-end imaging solution. Future-proof scalability; low GPU consumption

• Robust data management architecture gives healthcare IT department the option to host system on-premise or via cloud connection

Unique Deployment Flexibility

• Security

• Migration services - initially a strategy to secure business, now a valued service to preserve tech investment already made by hospital networks

• Customers own their imaging data; Mach7 ensures product security via regular penetration testing and ISO certification

25

VNA – Vendor Neutral Archive; EHR – Electronic Medical Record; AI – Artificial Intelligence; GPU – Graphics Processing Unit

==> picture [960 x 63] intentionally omitted <==

----- Start of picture text -----

KLAS – Defined
----- End of picture text -----

The Best in KLAS report recognises software and services companies who excel in helping healthcare professionals improve patient care.

KLAS surveys’ healthcare IT customers (providers) throughout the calendar year and releases its final findings in Q1 of the following calendar year. That is, Best in KLAS 2023 is based on data accumulated through data surveys and insights in CY 2022.

A Best in KLAS award signifies to the healthcare IT industry the commitment and partnership that the top vendors should provide.

Best in KLAS is highly competitive and based on customer experiences and satisfaction. The goal of most healthcare IT providers is to be listed in the “Solution Comparison” section as these are the healthcare IT companies that have reached the minimum customer survey threshold and scored high enough to be ranked as one of the best for their competitive field.

The Best in KLAS report recognizes software and services companies who excel in helping healthcare professionals improve patient care.

All rankings are a direct result of the feedback of thousands of customers and providers over the last year.

While “Best in KLAS” designates the #1 overall rank based on weighted scores, being positioned in the top 4 is considered the best of the pack and creates tremendous visibility in the markets as the IT companies that present the best value and customer satisfaction.

26

Our Revenue Model

==> picture [960 x 23] intentionally omitted <==

Revenue model caters to client funding needs

Flexible revenue model allows for both subscription (“SaaS”) and capital licences, generally on 5-year terms.

Equivalent Contracts:	Equivalent Contracts:	Capital Licence	Capital Licence	Subscription Licence	Subscription Licence
Activity/Timing	Fee Type	Revenue Recognition	Contribution CARR/ARR	Revenue Recognition	Contribution CARR/ARR
Sales Order Signed/ Software delivered	Licence Fee	100% eg: $1M	CARR eg: $0.2M p.a.	0%	CARR eg: $2.4M over 5yrs = $0.48M p.a.
Implementation/ Migration/Training	Professional Service Fee (one-off)	Milestone related eg: $0.3m	0%	Milestone related eg: $0.3m	0%
Software Live/ First Productive Use(FPU)	Annual Support Fee (20% of contract value)	20% annually eg: $0.2M p.a. over 5yrs = $1M	ARR eg: $0.2M p.a.
	Licence Fee			20% annually eg: $.048M p.a.	ARR eg: $0.48M p.a.
	Year 1 Revenue	$1.5M		$0.78M
Total Contract Value (TCV)	Over 5-Years	$2.3M		$2.7M

CARR= Contracted Annual Recurring Revenue: ARR + annual subscription licence fees and annual support fees where customer is yet to reach FPU ARR= Annual Recurring Revenue: annual subscription licence fees + annual support fees recognised as revenue upon the customer achieving FPU TCV= Total Contract Value: capital software licence fee/ annual subscription fee, professional service fees and annual support fees over life of contract; FPU= First Productive Use; SaaS = Software as a Service

27

Mach7 University

==> picture [960 x 23] intentionally omitted <==

==> picture [960 x 179] intentionally omitted <==

• Innovative solution to deliver training that fits work schedules and lifestyles.

Course Catalog Examples

• Clinical Studio Overview

• eUnity 7.0 Overview

• Unlimited attendees and unlimited access to informational videos, instructor-led training courses, and interactive knowledge-sharing sessions.

• eUnity Mammography

• Hanging Protocols for Administrators

• Mach7 Tech QC

• Universal Worklist Overview

• Advanced Visualization Overview

• Courses are tailored to specific roles, such as System Administrators and Clinical Super-Users. Many courses offer ASRT CE credits to help technologists retain their registry status.

• DICOM Routing

• eUnity 7.2 New Features

• eUnity System Administrator Overview

• • Mach7 VNA V12

• Management Studio for Administrators

• Predictable forecasting and budgeting of training costs via simple annual subscription.

• Universal Worklist for Administrators

28

Our Leadership Team

==> picture [960 x 23] intentionally omitted <==

==> picture [99 x 100] intentionally omitted <==

Mike Lampron Chief Executive Officer

Mike is the CEO of Mach7 Technologies. With over 20 years of experience in business and operational management for Healthcare IT companies, Mike brings a broad experience ranging from private start-up organizations to established companies such as IBM and GE. Mike was previously the CEO for a National Teleradiology Company and has a proven ability to drive results through a combination of astute analysis, innovative execution, and cross-functional teamwork. Mike is responsible for our customers’ success while driving excellence throughout Mach7.

==> picture [100 x 99] intentionally omitted <==

Dyan O’Herne Chief Financial Officer

Dyan is the Chief Financial Officer of Mach7 prior to which she spent seven years in financial controller roles. With the benefit of tenure and leadership positions, Dyan has a deep knowledge of the Company’s finances, operations, history and culture. She is a Chartered Accountant with more than 20 years’ experience in senior finance roles including with Aon Insurance Managers and PricewaterhouseCoopers immediately prior to joining Mach7 .

==> picture [99 x 99] intentionally omitted <==

David Madaffri Ravi Krishnan Chief Operating General Officer Manager, APAC

David is the Chief Operating Officer of Mach7, having held the role of Global Vice President of Sales previously. David began his career as a Radiologic Technologist and later managed the Imaging Services at Sharp Memorial Hospital in San Diego, CA. After leaving Sharp, he worked in Process Improvement Consulting, Implementation Services, and later Sales for both IDX and GE. For the past 12 years, David has worked for Philips Healthcare in a variety of sales leadership roles. Just prior to joining Mach7, David served as Philips’ Vice President of Sales for Enterprise Diagnostic Informatics for North America.

Ravi is a founding partner of Mach7 Technologies and is an accomplished image management professional with nearly 2 decades of domain-based experience with the technology intricacies which drive medical imaging.

Ravi is a Medical Imaging Informatics and image workflow expert. He has been instrumental in the growth of industryleading healthcare teams in Asia Pacific including GE Healthcare and Agfa Healthcare. As one of the two cofounders of Mach7, Ravi has built the design philosophy and technical strategy for Mach7.

==> picture [100 x 100] intentionally omitted <==

Lisa Thompson Vice President, Services

Lisa is the Vice President of Services for Mach7, including Professional Services and Client Support. Lisa brings over 18 years of experience in the healthcare software industry working with radiology, cardiology, patient access and enterprise software. Before joining Mach7, Lisa was Senior Director of Professional Services at GE Healthcare and VP Services and Support for QuadraMed/Harris Healthcare. Lisa has led teams responsible for professional services, support, implementation quality, operational excellence, business integration, and process management. Lisa holds a Black Belt in Six Sigma and is experienced in Lean and Change Management.

==> picture [100 x 100] intentionally omitted <==

Bob Tranchida Vice President, Marketing

Bob is Mach7’s Vice President of Marketing. With over 25 years of experience in the direct medical provider and healthcare IT space, he is a seasoned expert with vast experience and knowledge in many types of organizations, from IT startups to Fortune 500 organizations like Philips. Bob has held many leadership roles within these organizations, spanning product management, program management, strategic account management and marketing. He brings a deep well of knowledge, passion and energy to the leadership team and is focused on building out Mach7’s strategic global marketing programs.

==> picture [100 x 100] intentionally omitted <==

Andrew Volkening Vice President, Product

Andrew is a veteran imaging informatics leader with deep industry knowledge gained from over 20 years in healthcare imaging. He began his career as a Field Service Engineer and became PACS Administrator at Sunnybrook Health Sciences Center, one of Canada’s foremost teaching and research hospitals as well as the nation’s largest trauma center. Andrew’s direct experience managing PACS has given him the unique ability to understand the customer perspective and focus on relevant solutions that address their specific clinical imaging needs. Andrew is also an imaging researcher who has earned awards for his work developing Canadian guidelines for lossy compression.

29

Our Board of Directors

==> picture [960 x 23] intentionally omitted <==

==> picture [100 x 100] intentionally omitted <==

David Chambers

Outgoing Non-Executive Chairman

David has more than 30 years’ extensive experience in the Healthcare and Life Science industry and a proven track record in healthcare IT systems through a series of senior executive roles in Australia, North America, Europe, and Asia. David up until recently acted as Managing Director, Asia-Pacific, of Allscripts Healthcare Solutions, a NASDAQ listed billion-dollar global leader in Healthcare Technology, retiring after close to seven years, on 30th June 2020. Prior to that David was General Manager, Asia and ANZ with Carestream Health. He was former chief executive of ASX-Listed health software business Pro Medicus Limited. David also served eleven years with Agfa Healthcare, including managing their Informatics group in Asia Pacific, and culminating in his elevation to Vice President of Agfa North America.

==> picture [100 x 100] intentionally omitted <==

Mike Lampron Managing Director

Mike is the Chief Executive Officer and Managing Director of Mach7 Technologies. With over 20 years of experience in business and operational management for Healthcare IT companies, Mike brings a broad experience ranging from private start-up organizations as well as long established companies such as IBM and GE. Mike was previously the Chief Executive Officer for a National Teleradiology Company and has a proven ability to drive results through a combination of astute analysis, innovative execution and cross-functional teamwork. Mike is responsible for our customers’ success while driving excellence throughout Mach7.

==> picture [100 x 100] intentionally omitted <==

Philippe Houssiau Non-Executive Director

Philippe held a variety of executive roles as Partner with PriceWaterhouse and PwC, CEO of Agfa Healthcare, where he transitioned the business from being an Analog Film manufacturing outfit to become a world leader in Imaging and Health IT, CEO of Alliance Medical, the leading European Imaging Services Provider and CEO/Chairman of the Rhapsody Healthcare Interoperability business, now Lyniate. Philippe also ran the CSC/DxC Healthcare business in the UKI and Netherlands and held many board and Chair positions, in Imaging and Healthcare. He currently serves as the CEO of MAK-System, the leading Blood Management Software company and as Chairman of Corilus (Primary Care). Philippe is based in Antwerp, Belgium.

==> picture [100 x 100] intentionally omitted <==

Rob Bazzani Non-Executive Director

Rob spent 20 years with the global consulting firm KPMG, where he served as Chairman of KPMG Victoria, National Managing Partner for KPMG Australia’s Enterprise Division and National Managing Partner for KPMG’s M&A Division. Whilst in these roles, Rob was a member of KPMG’s National Executive Committee which oversees and is responsible for the Firm’s turnover, strategic decision making, profitability and operations. Rob has a demonstrated track record of leading and growing large scale and complex businesses. He has played a significant role in advising clients on commercial maters, corporate governance, M&A and has engaged with Government and Regulators. With extensive experience in corporate advisory, Rob has deep commercial and industry knowledge across financial services, asset and wealth management, property, insurances and consumer & industrial markets.

==> picture [100 x 100] intentionally omitted <==

Eliot Siegel, MD Non-Executive Director

Dr. Eliot Siegel is the Professor and Vice Chair of information systems at the University of Maryland School of Medicine, Department of Diagnostic Radiology, and the Chief of Radiology and Nuclear Medicine for the Veterans Affairs Maryland Healthcare System. Under his guidance, the VA Maryland Healthcare System became the first filmless healthcare enterprise in the World. He has written over 300 articles and book chapters about PACS and digital imaging and has edited six books on the topic. Dr. Siegel is a fellow of the the American College of Radiology and is a Board member of Carestream Health, a billiondollar global company in digital radiography and computed radiography systems and serves on numerous advisory boards in medical imaging.

~~30~~

==> picture [211 x 52] intentionally omitted <==

==> picture [491 x 27] intentionally omitted <==

Contact Us

Investor Relations, Mach7: Rebecca Thompson +61 (0) 416 079 329 Rebecca.Thompson@mach7t.com

Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC

This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer Mach7 Technologies

==> picture [221 x 54] intentionally omitted <==

----- Start of picture text -----

Issued 18 February 2021,
approved by the Board
31
----- End of picture text -----